搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 30 天
时间不限
过去 1 小时
过去 24 小时
过去 7 天
按相关度排序
按时间排序
The Pharma Letter
1 小时
2024: Emergent trends in pharma and biotech
The life sciences industry experienced volatility in 2024, marked by pipeline growth, biologics breakthroughs, and evolving ...
The Pharma Letter
6 小时
How can CDMOs drive ADC success from lab to launch?
Antibody-drug conjugates (ADCs) combine monoclonal antibody (MAb) specificity with cytotoxic drug potency via a linker, ...
The Pharma Letter
6 小时
UK regulator warns against illegal weight loss meds
The UK's MHRA warns against purchasing weight-loss drugs without a prescription due to health risks, amid a global rise in ...
The Pharma Letter
9 小时
Zorifer poised to fill critical gap for advanced NSCLC with CNS metastases in China, says ...
China’s National Medical Products Administration (NMPA) has recently approved Zorifer (zorifertinib), an oral epidermal ...
The Pharma Letter
11 小时
Novartis reports Phase III success for SMA gene therapy
Novartis reports positive Phase III trial results for its gene therapy in spinal muscular atrophy Type 2, plans regulatory ...
The Pharma Letter
11 小时
India's 50% drug price hike faces backlash, NPPA under fire
India's Parliamentary panel has come down heavily on the National Pharmaceutical Pricing Authority (NPPA) and directed it to ...
The Pharma Letter
11 小时
argenx announces new Japanese approval for Vyvdura
Dutch immunology specialist argenx announced that Japan’s Ministry of Health, Labor and Welfare (MHLW) approved Vyvdura ...
The Pharma Letter
22 小时
Daiichi Sankyo’s Datroway gains Japanese approval
Japanese drugmaker Daiichi Sankyo (TYO: 4568) revealed on Friday that its Datroway (datopotamab deruxtecan; dato-dxd) has ...
The Pharma Letter
10 小时
Rybrevant combo gains EU nod in first-line lung cancer
Johnson & Johnson secures EU approval for Rybrevant and Lazcluze combo as first-line NSCLC treatment, based on Phase III MARIPOSA trial data. The approval follows FDA setbacks for a subcutaneous ...
The Pharma Letter
2 天
FDA approves new injectable version of Opdivo
The US Food and Drug Administration (FDA) on Friday approved nivolumab and hyaluronidase-nvhy, under the trade name Opdivo ...
The Pharma Letter
3 天
AusperBio raises $73 million to advance hepatitis B therapy
AusperBio raises $73 million in series B funding to advance Phase II trials of AHB-137, its antisense oligonucleotide therapy ...
The Pharma Letter
3 天
Second FDA approval for BeiGene’s Tevimbra in 2024
The US Food and Drug Administration (FDA) has approved Tevimbra (tislelizumab-jsgr), in combination with platinum and ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈